GLP-1 RAs: The newest powerhouse in metabolic medicine.

IF 0.6 Q4 NURSING

NURSE PRACTITIONER Pub Date : 2024-08-01 Epub Date: 2024-07-25 DOI:10.1097/01.NPR.0000000000000216

Evan S Drake, Adriane B Marino, Jenna D Theroux, Kaitlin Roberts

引用次数: 0

Abstract

Abstract: In the last decade, the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) drug class has revolutionized treatment for type 2 diabetes mellitus and some of its comorbidities, including obesity and cardiovascular disease. Continued advancements in the GLP-1 RA space show clinical promise for patients, though challenges-including barriers to care such as drug expense and availability-exist. This article provides an overview of available GLP-1 RAs and their mechanisms of action, indications, adverse reactions, and risks, providing practical pearls for providers along the way.

查看原文本刊更多论文

GLP-1 RAs：新陈代谢医学的最新动力。

摘要：在过去十年中，胰高血糖素样肽-1（GLP-1）受体激动剂（RA）类药物彻底改变了 2 型糖尿病及其一些合并症（包括肥胖症和心血管疾病）的治疗方法。GLP-1 RA 领域的不断进步为患者带来了临床希望，但同时也存在着挑战，包括药物费用和可用性等治疗障碍。本文概述了现有的 GLP-1 RA 及其作用机制、适应症、不良反应和风险，并为医疗服务提供者提供了实用的指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NURSE PRACTITIONER NURSING-

CiteScore

0.90

自引率

0.00%

发文量

183

期刊介绍： With a circulation of 20,000, The Nurse Practitioner is the leading monthly source for clinical, practical, cutting-edge information for advanced practice nurses and other primary care clinicians. Each issue presents peer-reviewed articles that range from clinical topics and research to political and practice issues. In addition, The Nurse Practitioner provides regular features, columns, continuing education, staff development education, and more.